In a peer-reviewed study published today in Nature Communications, a team of scientists from French-American techbio Owkin and pathology labs in France present a blind validation of MSIntuit CRC, a first-in-class AI-driven digital pathology diagnostic developed by Owkin, as a pre-screening tool aimed at optimizing the precision of diagnosis and treatment of colorectal cancer.
J&J’s dealmaker: Plenty of ‘firepower,’ but mostly focused on tuck-in M&A
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
June 7, 2024